(Q55482459)

12 July 2018

title

Suramin inhibits glioma cell proliferation in vitro and in the brain. (English)

1 reference

12 July 2018

1 reference

S Takano

1

1 reference

12 July 2018

S Gately

2

1 reference

12 July 2018

H Engelhard

3

1 reference

12 July 2018

A M Tsanaclis

4

1 reference

12 July 2018

S Brem

5

1 reference

12 July 2018

publication date

1 January 1994

1 reference

12 July 2018

Journal of Neuro-Oncology

published in

1 reference

12 July 2018

volume

21

1 reference

12 July 2018

issue

3

1 reference

12 July 2018

page(s)

189-201

1 reference

12 July 2018

https://scigraph.springernature.com/pub.10.1007/bf01063768

exact match

0 references

cites work

Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01063768

Double labeling with iodo- and bromodeoxyuridine for cell kinetics studies

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01063768

Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect.

21 January 2018

1 reference

12 December 2020

A pilot study of suramin in the treatment of metastatic renal cell carcinoma

1 reference

12 December 2020

Suramin binds to platelet-derived growth factor and inhibits its biological activity

1 reference

12 December 2020

Inhibition of angiogenesis with combination treatments of angiostatic steroids and suramin

1 reference

12 December 2020

Neovascularization and tumor growth in the rabbit brain. A model for experimental studies of angiogenesis and the blood-brain barrier

1 reference

12 December 2020

Use of adaptive control with feedback to individualize suramin dosing

1 reference

12 December 2020

Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors

1 reference

12 December 2020

Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors

1 reference

12 December 2020

Double screening of suramin derivatives on human colon cancer cells and on neural cells provides new therapeutic agents with reduced toxicity

1 reference

12 December 2020

Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells

1 reference

12 December 2020

Immunohistochemical localization of basic fibroblast growth factor in astrocytomas.

1 reference

12 December 2020

Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor

1 reference

12 December 2020

C6 glioma cells produce basic fibroblast growth factor that can stimulate their own proliferation.

1 reference

12 December 2020

Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop

1 reference

12 December 2020

Acidic and basic fibroblast growth factors are present in glioblastoma multiforme

1 reference

12 December 2020

Inhibition of lung and liver tumor colonies in mice pretreated with suramin

1 reference

12 December 2020

Suramin inhibits proliferation of rat glioma cells and alters N-CAM cell surface expression.

1 reference

12 December 2020

Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues

1 reference

12 December 2020

Effects of modulation of basic fibroblast growth factor on tumor growth in vivo.

1 reference

12 December 2020

Antiproliferative effects of suramin on androgen responsive tumour cells

1 reference

12 December 2020

Suramin affects DNA synthesis in HeLa cells by inhibition of DNA polymerases.

1 reference

12 December 2020

Suramin: an anticancer drug with a unique mechanism of action.

1 reference

12 December 2020

Circulating glycosaminoglycan anticoagulants associated with suramin treatment

1 reference

12 December 2020

Inhibition of angiogenesis by suramin

1 reference

12 December 2020

Basic fibroblast growth factor: a potential autocrine regulator of human glioma cell growth.

1 reference

12 December 2020

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

12 December 2020

Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines.

1 reference

12 December 2020

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression

1 reference

12 December 2020

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

1 reference

12 December 2020

Inhibition of Breast Cancer Growth by Suramin

1 reference

12 December 2020

The effect of suramin, tumor necrosis factor and interferon gamma on human prostate carcinoma

1 reference

12 December 2020

Suramin in advanced platinum-resistant ovarian cancer

1 reference

12 December 2020

Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines

1 reference

12 December 2020

Adaptive control with feedback strategies for suramin dosing.

1 reference

12 December 2020

Suramin: prototype of a new generation of antitumor compounds

1 reference

12 December 2020

Tumor angiogenesis: a quantitative method for histologic grading.

1 reference

12 December 2020

Membranous neuronal and neuroglial inclusions produced by intracerebral injection of suramin

1 reference

12 December 2020

Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells

1 reference

12 December 2020

Characterization of the receptors for vascular endothelial growth factor

1 reference

12 December 2020

A feline model for experimental studies of peritumor brain edema

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01063768

1 reference

12 July 2018

Dimensions Publication ID

0 references

1 reference

12 July 2018